Tobacco Investments in the Pharmaceutical Sector

Posted on September 01, 2021

Tobacco companies are doubling efforts to create perceptions that they are contributing to health. In the past few months, the tobacco industry has been investing in the "health"/ medical/ pharmaceutical sectors through acquisitions and takeovers, creating new challenges with new tobacco tactics.

The webinar tackles these emerging deadly partnerships and implications for tobacco control.

Click the button below to request access to this webinar and its resources.


Reference Materials - Tobacco Investments in the Pharmaceutical Sector


Additional references


Tobacco is not Pharma

Dr. Adriana Blanco Marquizo, WHO FCTC Secretariat

Dr. Adriana Blanco Marquizo's keynote address


BAT's Vaccination Initiative: The Case of Bangladesh

Md. Hasan Shahriar, PROGGA

BAT Bangladesh associated itself with COVID-19 vaccination efforts to "support" public health efforts-- while simultaneously increasing its cigarette production.


PMI's Acquisition of Vectura

Louis Laurence, Tobacco Control Research Group, University of Bath

PMI's takeover of Vectura, a pharmaceutical company specializing in inhaled therapeutics, and its repercussions.


Tobacco Investments in Pharma: Countering the Narrative and Anticipating Isues

Douglas Bettcher, World Health Organization

Using the WHO FCTC as a "pathfinder" to counter commercial determinants of health and ways to counter the tobacco industry's "redemption narrative"


Big Tobacco's Investments in and Acquisitions of Pharmaceutical Companies

GGTC, a partner in STOP, along with inputs from participants of the 'Tobacco Investments in the Pharmaceutical Sector' webinar

Issue brief highlighting the tobacco industry's pharmaceutical acquisitions and how they interfere with tobacco control efforts.


Big Tobacco's Investments in and Acquisitions of Pharmaceutical Companies

Global Center for Good Governance in Tobacco Control, a partner in STOP (a tobacco industry watchdog)

Issue brief detailing Big Tobacco's recent acquisitions in pharmaceutical or related companies, which can be seen as increasing barriers to tobacco control and WHO FCTC implementation.


This is private content!

To view webinar materials, click the button below and enter your email.

Request Access
GGTC Partners